Genelux (GNLX) Share-based Compensation (2022 - 2026)

Genelux's (GNLX) quarterly Share-based Compensation came in at $1.4 million in Q1 2026, down 2.04% year-on-year from $1.4 million in Q1 2025, and down 9.19% quarter-over-quarter from $1.5 million in Q4 2025.

Genelux (GNLX) Share-based Compensation (2022 - 2026) Analysis & Trends

Genelux's Share-based Compensation history runs 5 years deep, the most recent figure standing at $1.4 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 2.04% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a 1.08% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, up 2.32% from the prior year.
  • Share-based Compensation eased to $1.4 million in Q1 2026 per GNLX's latest filing, from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $21.4 million in Q3 2023 and bottomed at -$42000.0 in Q4 2023.
  • The 5-year median for Share-based Compensation is $1.4 million (2026), against an average of $2.4 million.
  • Across the five-year window, Share-based Compensation tumbled 197.67% in 2023 and surged 3504.76% in 2024, its largest moves.
  • Year by year, Share-based Compensation stood at $43000.0 in 2022, then tumbled by 197.67% to -$42000.0 in 2023, then jumped by 3504.76% to $1.4 million in 2024, then advanced by 7.34% to $1.5 million in 2025, then declined by 9.19% to $1.4 million in 2026.
  • Per Business Quant, the three latest GNLX Share-based Compensation figures stand at $1.4 million (Q1 2026), $1.5 million (Q4 2025), and $1.6 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn - 6.39 Mn
2 Nanobiotix 1,909.44 Bn 1,909.38 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - 305,000.00
4 BeOne Medicines 471.58 Bn 466.79 Bn 1.35 Bn 9.26 Mn
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn 166.40 Mn
6 Regeneron Pharmaceuticals 69.93 Bn 61.18 Bn 3.31 Bn 257.40 Mn
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.80 Bn 50.61 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.37 Bn 34.36 Bn 959.66 Mn -
10 Genelux 128.92 Mn 128.92 Mn - 1.39 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.39 Mn
Mar 31, 2026 1.39 Mn
Dec 31, 2025 1.54 Mn
Dec 31, 2025 1.54 Mn
Sep 30, 2025 1.62 Mn
Sep 30, 2025 1.62 Mn
Jun 30, 2025 1.29 Mn
Jun 30, 2025 1.29 Mn
Mar 31, 2025 1.42 Mn
Mar 31, 2025 1.42 Mn
Dec 31, 2024 1.43 Mn
Dec 31, 2024 1.43 Mn
Sep 30, 2024 1.76 Mn
Sep 30, 2024 1.76 Mn
Jun 30, 2024 1.30 Mn
Jun 30, 2024 1.30 Mn
Mar 31, 2024 1.49 Mn
Mar 31, 2024 1.49 Mn
Dec 31, 2023 -42,000.00
Dec 31, 2023 -42,000.00